ANIX — Anixa Biosciences Inc

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Anixa Biosciences Inc

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$2.73
Market Cap$91.5M
Float31.7M
Shares Outstanding33.5M
Price/Sales (TTM)377.78
vs. Analyst Target+293.8% to analyst PT
Dividend RateNone
Analyst Target Price$10.75 (3 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$10.1M -$90,157 -$10.0M
2021 $512,000 -$12.9M $127,000 -$13.1M
2022 $2.47B -$13.6M $2.47B -$13.7M
2023 $210,000 -$9.8M $49,000 -$11.0M
2024 N/A -$12.6M -$37,000 -$12.7M
2025 N/A -$10.9M -$36,000 -$11.7M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Apr 2025 N/A -$2.8M
Jul 2025 N/A -$2.3M
Oct 2025 N/A -$2.7M
Jan 2026 N/A -$2.6M

Ownership & Float

Insider Ownership5.4%
Institutional Ownership15.5%
Short Float3.3%
% of All Funds Holding0.72%
Number of Funds Holding59

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$2.82Near-term / short-term trend
Weekly40-Week SMA$3.30Medium-term trend
Weekly80-Week SMA$3.10Cyclical trend (business cycle)
Weekly200-Week SMA$3.49Secular trend (multi-year)
Monthly10-Month SMA$3.25Near-term monthly trend
Monthly20-Month SMA$3.11Medium-term monthly trend
Monthly40-Month SMA$3.27Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$4.50 resistance 3.13x 4 months ago
$2.40 support 1.22x 15 months ago
$2.20 support 1.21x 21 months ago

Historical Earnings Reactions (107 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.57% 0.00% 40.19% 30.54% -14.29%
1 Day 0.14% 0.00% 35.51% 22.22% -12.50%
1 Week 5.12% 0.00% 49.53% 93.94% -23.15%
2 Weeks 10.66% -0.61% 42.99% 483.33% -31.25%
1 Month 7.82% -1.98% 42.06% 377.27% -38.71%

Next earnings: May 27, 2026

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan10.2%55.8%43
Feb-1.9%30.2%43
Mar0.6%34.9%43
Apr2.5%44.2%43
May3.6%45.2%42
Jun-2.5%28.6%42
Jul-0.5%31.0%42
Aug5.4%52.4%42
Sep11.0%47.6%42
Oct-1.4%40.5%42
Nov4.9%48.8%43
Dec-4.2%37.2%43

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.13% 36.2% 2028
Tuesday -0.11% 38.0% 2203
Wednesday 0.26% 41.0% 2200
Thursday 0.14% 39.6% 2159
Friday 0.70% 42.6% 2149

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 15.5%

Insider Transactions — Smart Summary

Total insider ownership: 5.4%

Founder-led management: Amit Kumar (CEO, Chairman & Co-Chair of CBAB)

12-Month Insider Activity Summary

Total Filings7
Net Value+$60,050
Net Shares Change55,000
% of Float0.2%
C-Suite Filings3
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
Titterton Lewis H jr +$62,200 2 2 buy
KUMAR AMIT Chief Executive Officer +$60,050 3 3 buy
Baskies Arnold M +$47,350 2 2 buy

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-07-14 – 2025-07-21 3 3 +$64,100 1 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-01-29 Baskies Arnold M +$30,400 Transaction at $3.04, now -10.2%
2025-07-31 KUMAR AMIT Chief Executive Officer +$15,800 Transaction at $3.16, now -13.6%
2025-07-14 KUMAR AMIT Chief Executive Officer +$15,750 Transaction at $3.15, now -13.3%
2025-06-05 KUMAR AMIT Chief Executive Officer +$28,500 Transaction at $2.85, now -4.2%
2025-07-21 Baskies Arnold M +$16,950 Transaction at $3.39, now -19.5%
2025-08-04 Titterton Lewis H jr +$30,800 Transaction at $3.08, now -11.4%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Anixa Biosciences Inc (ANIX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for ANIX on Trend Edge →